Positive Early Safety and Tolerability in Phase 1 Deltacel-01 Trial

Kiromic BioPharma, a biotherapeutic firm specializing in immuno-oncology, has announced positive initial results from a Phase 1 clinical trial for Deltacel™, a cell therapy treatment for stage 4 metastatic non-small cell lung cancer (NSCLC). The trial, conducted at the Beverly Hills Cancer Center, has shown no adverse events and good tolerability 23 days post-infusion in the first patient. The company anticipates preliminary efficacy results by January 2024 and plans to enroll two more patients in the coming months.

The CEO of Kiromic, Pietro Bersani, expressed optimism regarding the trial's progress and the safety profile of Deltacel. He also mentioned the company's intention to discuss updates with investment professionals during the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. Interested parties can arrange meetings with key executives through LHA Investor Relations.

Dr. Afshin Eli Gabayan, Principal Investigator at Beverly Hills Cancer Center, highlighted the importance of the initial safety and tolerability data, suggesting that if replicated, Deltacel could offer a new treatment option for NSCLC patients. The Phase 1 trial, "Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T Cell Infusions in Combination With Low Dose Radiotherapy in Subjects With Stage 4 Metastatic Non-Small Cell Lung Cancer" (NCT06069570), involves administering Deltacel alongside low-dose radiation therapy.

Deltacel is an experimental gamma delta T-cell therapy derived from donor cells, designed to target solid tumors with a focus on NSCLC, which accounts for a significant proportion of lung cancer cases. Preclinical studies have demonstrated its safety and efficacy when combined with radiation.

Kiromic BioPharma utilizes its proprietary DIAMOND® AI 2.0 technology for drug development, aiming to expedite the process and reduce costs associated with live drug development. The company is headquartered in Houston, Texas, and maintains an active presence on social media platforms.

Beverly Hills Cancer Center is recognized for providing advanced cancer treatments and clinical trials, attracting patients worldwide. The center boasts a multidisciplinary team of medical professionals and offers comprehensive patient care and support services.

The press release from Kiromic BioPharma details the ongoing clinical trial and the company's commitment to developing innovative cell therapies for cancer treatment. The positive initial results from the Deltacel trial represent a significant step forward in the quest for new treatment options for NSCLC patients.